

**Silva Pharmaceuticals Limited**

**Un-Audited Financial Statements (First Quarter)**


For the Period from 01 July, 2019 to 30 September, 2019

# Silva Pharmaceuticals Limited

Statement of Financial Position (Un-Audited)

As at 30 September, 2019

Particulars	Notes	Amount in Taka	
		30-Sep-19	30-Jun-19
<b>ASSETS</b>			
<b>Non Current Assets</b>		<b>1,254,714,072</b>	<b>1,241,202,338</b>
Property, Plant and Equipment	3.00	1,229,464,566	1,232,602,338
Capital work-in-Progress	4.00	25,249,506	8,600,000
<b>Current Assets</b>		<b>1,103,551,150</b>	<b>1,060,520,369</b>
Inventories	5.00	405,122,284	397,462,763
Trade and Other Receivables		273,890,091	259,260,489
Advances, Deposits and Prepayments		124,889,790	109,605,666
Investment in FDR		258,300,000	251,800,000
Cash and Cash Equivalents	6.00	41,348,985	42,391,451
<b>Total Assets</b>		<b>2,358,265,222</b>	<b>2,301,722,707</b>
<b>SHAREHOLDERS EQUITY AND LIABILITIES:</b>			
<b>Equity attributable to the Shareholders</b>		<b>2,173,643,317</b>	<b>2,133,442,946</b>
Share Capital	7.00	1,300,000,000	1,300,000,000
Retained Earnings	8.00	873,643,317	833,442,946
<b>Non-Current Liabilities</b>		<b>79,911,139</b>	<b>78,520,043</b>
Deferred Tax Liabilities	9.00	79,911,139	78,520,043
<b>Current Liabilities</b>		<b>104,710,766</b>	<b>89,759,718</b>
Trade and Other Payables		4,520,870	4,391,454
Provision for Expenses		100,189,896	85,368,264
<b>Total Liabilities</b>		<b>184,621,905</b>	<b>168,279,761</b>
<b>Total Equity &amp; Liabilities:</b>		<b>2,358,265,222</b>	<b>2,301,722,707</b>
<b>Net Assets Value (NAV) per share</b>	<b>14.00</b>	<b>16.72</b>	<b>16.41</b>



Chairman



Managing Director



Director



Chief Financial Officer

  
Company Secretary

Place: Dhaka;

Dated: November 13, 2019

# Silva Pharmaceuticals Limited

Statements of Profit or Loss and other Comprehensive Income (Un-Audited)

For the First Quarter ended 30 September, 2019

Particulars	Notes	Amount in Taka	
		July - September, 2019	July - September, 2018
Turnover		203,345,852	179,675,492
Cost of goods sold	10.00	(117,490,189)	(108,585,137)
Gross Profit		85,855,663	71,090,355
Operating expenses	11.00	(35,454,111)	(31,032,854)
Operating Income		50,401,552	40,057,501
Financial expenses		-	(3,354,061)
Net Operating Profit		50,401,552	36,703,440
Interest and Other income		5,878,968	1,510,066
Net Profit before Contribution to WPPF		56,280,520	38,213,506
Contribution to Worker's Profit Participation fund (WPPF)		(2,680,025)	(1,819,691)
Net Profit before Income Tax		53,600,495	36,393,815
Income Tax Expenses:		(13,400,124)	16,235,799
Current Tax Expenses	12.01	(12,009,028)	(9,415,795)
Deferred Tax expenses	12.02	(1,391,096)	25,651,594
Net Profit after tax		40,200,371	52,629,614
Earnings per Share (EPS)	13.00	0.31	0.48



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: November 13, 2019

**Silva Pharmaceuticals Limited**  
Statement of Changes in Equity (Un-Audited)  
For the First Quarter ended 30 September, 2019

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2019	1,300,000,000	833,442,946	2,133,442,946
Net profit after tax during the period	-	40,200,371	40,200,371
Balance as at 30 September, 2019	1,300,000,000	873,643,317	2,173,643,317

**Silva Pharmaceuticals Limited**  
Statement of Changes in Equity  
For the First Quarter ended 30 September, 2018

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2018	1,000,000,000	710,561,004	1,710,561,004
Net profit after tax during the period	-	52,629,614	52,629,614
Issue of Share Capital	300,000,000	-	300,000,000
IPO Expenses Paid	-	(10,037,120)	(10,037,120)
Balance as at 30 September, 2018	1,300,000,000	753,153,498	2,053,153,498



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: November 13, 2019



# Silva Pharmaceuticals Limited

## Statement of Cash Flows (Un-Audited)

For the First Quarter ended 30 September, 2019

Particulars	Amount in Taka	
	July - September, 2019	July - September, 2018
<b>Cash flows from Operating Activities</b>		
Cash received from Customers	193,166,710	167,313,158
Cash received from non-operating income	1,428,508	1,781,942
Cash Paid to Suppliers	(112,749,278)	(100,839,720)
Cash Paid to Employees	(28,499,149)	(33,809,871)
Cash Paid for Others	(6,866,360)	(6,464,922)
Income Tax Paid	(10,645,856)	(7,601,409)
<b>Net cash inflow/(outflow) from operating activities (A)</b>	<b>35,834,575</b>	<b>20,379,178</b>
<b>Cash flows from Investing Activities</b>		
Acquisition of Property, Plant and Equipment	(13,727,535)	(12,680,250)
Cash Payments for Capital Work-in-progress	(16,649,506)	(8,546,360)
Cash Payments for FDR	(6,500,000)	-
<b>Net cash inflow/(outflow) from investing activities (B)</b>	<b>(36,877,041)</b>	<b>(21,226,610)</b>
<b>Cash flows from Financing Activities</b>		
Long Term Loan received/(Repaid)	-	2,722,500
Cash payment for Financial Expenses	-	(3,185,316)
Cash payment for IPO Expenses	-	(10,037,120)
Share Application Money received	-	350,212,773
Issuance of Share Capital	-	300,000,000
<b>Net cash inflow/(outflow) from financing activities (C)</b>	<b>-</b>	<b>639,712,837</b>
<b>Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)</b>	<b>(1,042,466)</b>	<b>638,865,405</b>
Cash and Cash Equivalents at the beginning of the period	42,391,451	50,296,960
<b>Cash and Cash Equivalents at the end of the period</b>	<b>41,348,985</b>	<b>689,162,365</b>
<b>Net Operating Cash Flows Per Share</b>	<b>15.00</b>	<b>0.18</b>



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary